Analysis of the Contribution of Individual Substituents in 4,6-Aminoglycoside-Ribosome Interaction
Open Access
- 1 December 2005
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (12) , 5112-5118
- https://doi.org/10.1128/aac.49.12.5112-5118.2005
Abstract
The 4,6-disubstituted 2-deoxystreptamines interfere with protein biosynthesis by specifically targeting the ribosomal A site. These drugs show subtle variations in the chemical groups of rings I, II, and III. In the present study we used site-directed mutagenesis to generate mutant strains of Mycobacterium smegmatis mc2155 SMR5 ΔrrnB with mutations in its single rRNA allele, rrnA. This genetic procedure gives rise to strains carrying homogeneous populations of mutant ribosomes and was used to study the contribution of individual chemical substituents to the binding of 4,6-disubstituted aminoglycosides. X-ray crystal structures of geneticin and tobramycin complexed to oligonucleotides containing the minimal bacterial ribosomal A site were used for interpretation of MICs determined for a panel of 4,6-aminoglycosides, including tobramycin, kanamycin A, kanamycin B, amikacin, gentamicin, and geneticin. Surprisingly, the considerable differences present within ring III did not seem to alter the interaction of the drug with the ribosome, as determined by site-directed mutagenesis of the A site. In contrast, subtle variations in ring I significantly influenced binding: (i) a 4′-hydroxyl moiety participates in the proper drug target interaction; and (ii) a 2′-amino group contributes an additional positive charge to ring I, making the drug less susceptible to any kind of sequence alteration within the decoding site, most notably, to conformational changes induced by transversion of U1495 to 1495A. The 4-amino-2-hydroxyl-1-oxobutyl extension at position 1 of ring II of amikacin provides an additional anchor and renders amikacin less dependent on the structural conformation of nucleotide U1406 compared to the dependencies of other kanamycins. Overall, the set of interactions forming the complex between drug substituents and nucleotides of the A site constitutes a network in which the interactions can partly compensate for each other when they are disrupted.Keywords
This publication has 21 references indexed in Scilit:
- The Structural Basis of Macrolide–Ribosome Binding Assessed Using Mutagenesis of 23S rRNA Positions 2058 and 2059Journal of Molecular Biology, 2004
- The Molecular Basis for A‐Site Mutations Conferring Aminoglycoside Resistance: Relationship between Ribosomal Susceptibility and X‐ray Crystal StructuresChemBioChem, 2003
- Role of 16S rRNA Helix 44 in Ribosomal Resistance to Hygromycin BAntimicrobial Agents and Chemotherapy, 2003
- Crystal Structure of Geneticin Bound to a Bacterial 16S Ribosomal RNA A Site OligonucleotideJournal of Molecular Biology, 2003
- Crystal Structure of a Complex between the Aminoglycoside Tobramycin and an Oligonucleotide Containing the Ribosomal Decoding A SiteChemistry & Biology, 2002
- Aminoglycoside Resistance with Homogeneous and Heterogeneous Populations of Antibiotic-Resistant RibosomesAntimicrobial Agents and Chemotherapy, 2001
- Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A SiteStructure, 2001
- Aminoglycosides: Perspectives on Mechanisms of Action and Resistance and Strategies to Counter ResistanceAntimicrobial Agents and Chemotherapy, 2000
- Aminoglycosides: Activity and ResistanceAntimicrobial Agents and Chemotherapy, 1999
- MISREADING OF RNA CODEWORDS INDUCED BY AMINOGLYCOSIDE ANTIBIOTICS1965